Q-omics provides the consensus-scored RPS29P11 profile across patient tissues and cancer cell-line models. RPS29P11 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPS29P11 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, RPS29P11 RNA expression shows 14,704 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, THCA, and LSCC as cancer lineages where RPS29P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS29P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS29P11 survival associations across molecular data types. RPS29P11 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS29P11 RNA expression–survival associations across cancer types. High RPS29P11 expression shows unfavorable associations in UCS, LUSC and BRCA, but favorable associations in KIRP, LUAD and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPS29P11 RNA expression.
This table summarizes RPS29P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS29P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS29P11 shows lower tumor expression in LUSC, LUAD, KICH and BRCA and higher tumor expression in THCA and KIRP. The THCA box plot shows higher RPS29P11 RNA expression in tumor versus normal tissue (log2 FC = +5.400, t-test p < 0.001).
This table shows molecular features associated with RPS29P11 in patient tissues and cancer cell lines. In patient samples, RPS29P11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
